Insulin-like growth factor-1 (IGF-1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR) pathway

2008 ◽  
Vol 75 (5) ◽  
pp. 810-817 ◽  
Author(s):  
Bing Han ◽  
Junfeng Tong ◽  
Mei J. Zhu ◽  
Changwei Ma ◽  
Min Du
2016 ◽  
Vol 26 (9) ◽  
pp. 1667-1672 ◽  
Author(s):  
Dongge Cai ◽  
Hongli Sun ◽  
Yanhua Qi ◽  
Xiaogui Zhao ◽  
Minjuan Feng ◽  
...  

BackgroundMetformin is a well-tolerated biguanide drug used for decades to treat type 2 diabetes mellitus. In recent years, long-term administration of metformin has been found to reduce carcinogenic risk for cancers derived from various tissues. However, its cellular and molecular mechanisms of anticancer action in the endometrial cancer (EC) have not yet been fully elucidated.Patients and MethodsSixty patients diagnosed as endometrial carcinoma were grouped into (n = 30) and non-treatment mixed (n = 30) for analysis. Thirty healthy donors are control groups. We attempt to investigate the interaction of metformin, insulin-like growth factor 1 (IGF-1) expression, and phosphorylated mammalian target of rapamycin (p-mTOR) and AMP-activated protein kinase (p-AMPK).ResultsWe found that high IGF-1 plasma concentrations in women with EC were reversed by conventional antidiabetic doses of metformin in the present work. In parallel, the activation of AMPK and suppression of mTOR seemed to play an important role for the effect of metformin in patients with EC.ConclusionsThis pilot trial presents biological evidence consistent with antiproliferative effects of metformin in women with EC in the clinical setting.


2007 ◽  
Vol 170 (1) ◽  
pp. 301-315 ◽  
Author(s):  
Liliana Schaefer ◽  
Wasiliki Tsalastra ◽  
Andrea Babelova ◽  
Martina Baliova ◽  
Jens Minnerup ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document